Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study

OBJECTIVES: Given the novelty of proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i), little is known regarding overall implementation or clinical characteristics among patients who initiate treatment. We aimed to assess the total number of patients initiated on PCSK9i along with a des...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Jakob Solgaard, Weeke, Peter Ejvin, Bang, Lia Evi, Høfsten, Dan Eik, Ripa, Maria Sejersten, Schjerning, Anne-Marie, Theilade, Juliane Elizabeth, Køber, Lars Valeur, Gislason, Gunnar Hilmar, Pallisgaard, Jannik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500097/
https://www.ncbi.nlm.nih.gov/pubmed/30940751
http://dx.doi.org/10.1136/bmjopen-2018-022702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500097/
https://www.ncbi.nlm.nih.gov/pubmed/30940751
http://dx.doi.org/10.1136/bmjopen-2018-022702

Ejemplares similares